Art. -Nr.: HY-145994

Obeldesivir

(Synonyms: ATV006)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Obeldesivir (ATV006) is a potent, orally active antiviral agent and ester proagents of GS-441524. Obeldesivir inhibits the replication of SARS-CoV-2 and its variants. Obeldesivir can be used for SARS-CoV-2 research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.53%
CAS. Nr.: 2647441-36-7
Formel: C₁₆H₁₉N₅O₅
Molecular Weight:361.35

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Obeldesivir Chemical Structure

CAS. Nr.: 2647441-36-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
Hepatocyte	CC₅₀	>100 μM Compound: 3; GS-5245, ODV	Cytotoxicity against human primary hepatocytes assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human primary hepatocytes assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
HepG2	CC₅₀	71 μM Compound: 3; GS-5245, ODV	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
Huh-7	CC₅₀	>44 μM Compound: 3; GS-5245, ODV	Cytotoxicity against human Huh-7 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
MRC5	CC₅₀	>44 μM Compound: 3; GS-5245, ODV	Cytotoxicity against human MRC5 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human MRC5 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
MT4	CC₅₀	>50 μM Compound: 3; GS-5245, ODV	Cytotoxicity against human MT4 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human MT4 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
PBMC	CC₅₀	>100 μM Compound: 3; GS-5245, ODV	Cytotoxicity against quiescent human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against quiescent human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
PBMC	CC₅₀	>100 μM Compound: 3; GS-5245, ODV	Cytotoxicity against stimulated human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against stimulated human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
PC-3	CC₅₀	>100 μM Compound: 3; GS-5245, ODV	Cytotoxicity against human PC-3 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human PC-3 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]

In Vitro

Obeldesivir (0.001-100 μM; 48 h; Vero E6 cells) inhibits the replication of authentic SARS-CoV-2 and its variants of concern. Obeldesivir has an overall >4-fold and >12-fold potency improvement in inhibiting the replication of Delta and Omicron variants, with EC₅₀ values of 0.349 μM and 0.106 μM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Obeldesivir (5-25 mg/kg; p.o. and i.v.; Sprague Dawley rats) has favorable pharmacokinetic profiles in rats with high oral bioavailability (F %) of 81.5% and maximum blood concentration (C_max) of 8.2 μM^[1].
Obeldesivir (250-500 mg/kg; p.o.; daily, for 4 days; hACE2 knock-in and Ad5-hACE2 mice) has antiviral activity and inhibits SARS-CoV-2 replication in mouse models^[1].
Obeldesivir (100-250 mg/kg; p.o.; daily, for 10 days) reduces lung damage and protects K18-hACE2 mice^[1].
Obeldesivir (10-150 mg/kg; p.o.; daily, for 3 days) reduces virus titers and lung damage caused by Delta variant infection in K18-hACE2 mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague Dawley rats^[1]
Dosage:

5 and 25 mg/kg
Administration:

Oral administration (25 mg/kg) and intravenous injection (5 mg/kg)
Result:

1.19

parameters i.v. (5 mg/kg) p.o. (25 mg/kg)

AUC_last (μM·h) 5.6 22.8

T_1/2 (h) 1.5 1.2

T_max (h) 0.5

C_max (μM) 8.7 8.2

F % 81.5

Animal Model:

hACE2 knock-in and Ad5-hACE2 mice^[1]
Dosage:

250 and 500 mg/kg
Administration:

Oral administration; daily, for 4 days
Result:

Inhibited gRNA and sgRNA, which is Biomarkers of coronavirus replication. Reduced the viral load and pathological damage of the lung.

Animal Model:

K18-hACE2 mice^[1]
Dosage:

100 and 250 mg/kg
Administration:

Oral administration; daily, for 10 days
Result:

Reduced viral RNA and increased the survival rate of mice. Reduced evidence of lung pathology and the production of inflammatory cytokines and chemokines in the lung tissues.

Animal Model:

K18-hACE2 mice^[1]
Dosage:

10, 30, 80 and 150 mg/kg
Administration:

Oral administration; daily, for 3 days
Result:

Reduced viral load in a dose-dependent manner and alleviated the symptoms in the lung.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 2647441-36-7
Appearance Solid
Molecular Weight 361.35
Formel C₁₆H₁₉N₅O₅
Color White to off-white
SMILES

N#C[C@@]1(C2=CC=C3N2N=CN=C3N)O[C@@H]([C@H]([C@H]1O)O)COC(C(C)C)=O
Synonyms

ATV006
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Microbe

2025 Oct 14.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (691.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7674 mL

13.8370 mL

27.6740 mL

5 mM

0.5535 mL

2.7674 mL

5.5348 mL

10 mM

0.2767 mL

1.3837 mL

2.7674 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Cao L, et, al. The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants. Sci Transl Med. 2022 May 17:eabm7621. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7674 mL	13.8370 mL	27.6740 mL	69.1850 mL
	5 mM	0.5535 mL	2.7674 mL	5.5348 mL	13.8370 mL
	10 mM	0.2767 mL	1.3837 mL	2.7674 mL	6.9185 mL
	15 mM	0.1845 mL	0.9225 mL	1.8449 mL	4.6123 mL
	20 mM	0.1384 mL	0.6918 mL	1.3837 mL	3.4592 mL
	25 mM	0.1107 mL	0.5535 mL	1.1070 mL	2.7674 mL
	30 mM	0.0922 mL	0.4612 mL	0.9225 mL	2.3062 mL
	40 mM	0.0692 mL	0.3459 mL	0.6918 mL	1.7296 mL
	50 mM	0.0553 mL	0.2767 mL	0.5535 mL	1.3837 mL
	60 mM	0.0461 mL	0.2306 mL	0.4612 mL	1.1531 mL
	80 mM	0.0346 mL	0.1730 mL	0.3459 mL	0.8648 mL
	100 mM	0.0277 mL	0.1384 mL	0.2767 mL	0.6918 mL

Keywords

Obeldesivir

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Obeldesivir

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Obeldesivir

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

parameters	i.v. (5 mg/kg)	p.o. (25 mg/kg)
AUC_last (μM·h)	5.6	22.8
T_1/2 (h)	1.5	1.2
T_max (h)		0.5
C_max (μM)	8.7	8.2
F %		81.5

Obeldesivir

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Obeldesivir

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Obeldesivir Related Classifications

HY-145994 Related Classifications